Kaempferol attenuates type 2 diabetic osteoporosis via METTL3/YTHDF2-regulated PTEN m⁶A methylation and ferritinophagy-ferroptosis inhibition.
Type 2 diabetic osteoporosis (T2DOP) features impaired bone quality and high fracture risk, with unclear pathogenesis and limited targeted therapies. This study explored the therapeutic effect and molecular mechanism of kaempferol against T2DOP via m⁶A modification and ferritinophagy-dependent ferroptosis using bioinfo...